Anti-invasion and anti-proliferation effects of 3-acetyl-5,8-dichloro-2-((2,4-dichlorophenyl)amino)quinolin-4(1H)-one (ADQ) via regulation of Akt and Twist1 in liver cancer cells

Jain Ha
Chung-Ang University

Sewoong Lee
Chung-Ang University

Jiyoung Park
Chung-Ang University

Jihye Seo
Chung-Ang University

Eunjeong Kang
Chung-Ang University

Haelim Yoon
Chung-Ang University

Ba Reum Kim
Chung-Ang University

Hyeon Kyu Lee
Korea Research Institute of Chemical Technology

Seong Eon Ryu
Hanyang University

Sayeon Cho (sycho@cau.ac.kr)
Chung-Ang University

Research Article

Keywords: Anti-cancer, Twist; Akt pathway, Chemical inhibitor

DOI: https://doi.org/10.21203/rs.3.rs-125649/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

When primary cancer faces limited oxygen and nutrient supply, it undergoes an epithelial-mesenchymal transition, which increases cancer cell motility and invasiveness. The migratory and invasive cancer cells often exert aggressive cancer development or even cancer metastasis. In this study, we investigated a novel compound, 3-acetyl-5,8-dichloro-2-((2,4-dichlorophenyl)amino)quinolin-4(1H)-one (ADQ), that showed significant suppression of wound healing and cellular invasion. This compound also inhibited anchorage-independent cell growth, multicellular tumor spheroid survival/invasion, and metalloprotease activities. The anti-proliferative effects of ADQ were mediated by inhibition of the Akt pathway. In addition, ADQ reduced the expression of mesenchymal markers of cancer cells, which was associated with the suppressed expression of Twist1. In conclusion, ADQ successfully suppressed carcinogenic activity by inhibiting the Akt signaling pathway and Twist1, which suggests that ADQ may be an efficient candidate for cancer drug development.

Introduction

Liver cancer is the seventh most commonly diagnosed cancer and the third leading cause of death from cancer worldwide in 2018. The primary cancer cells undergo physiological changes, which are mediated by suppression of E-cadherin and upregulation of N-cadherin along with the massive expression of matrix metalloproteinases (MMP) that can degrade the extracellular matrix (ECM). The different expression pattern of E-cadherin and N-cadherin is called “cadherin switching,” which is a hallmark of molecular alterations associated with cancer development. As a result, primary cancer develops the potential to escape from the primary site to other parts of the body and eventually develops into secondary cancers.

In normal cells, the Akt pathway participates in the regulation of cell proliferation via balancing cell cycle progression and apoptosis. When the Akt pathway is activated, it transduces intracellular signaling that induces cell proliferation. The activities of forkhead box O (FoxO) transcription factors are down-regulated via phosphorylation by Akt. The FoxO family exerts tumor-suppressive functions by inducing the expression of cyclin-dependent kinase inhibitors (CDKI), which ensure strict CDK regulation during the cell cycle process. Therefore, the suppression of FoxO transcription factors induced by hyperactivation of Akt leads to the inhibition of CDKI expression, resulting in continuous cell proliferation. Akt is often found highly phosphorylated in most liver cancer cell lines and liver cancer tissues from patients.

Therefore, the proper regulation of the Akt pathway is one of the crucial goals for anti-cancer strategies.

Several transcription factors that function in the development of cancer have been reported in recent years. The functions of the Twist family have been extensively studied in physiology and pathology, including organogenesis, cell stemness, senescence, angiogenesis, chemoresistance, and metastasis. As a transcription factor, Twist1 regulates the expression of E-cadherin and N-cadherin that are associated with the progression of cancer. It has been reported that high expression of Twist1 is associated with aggressive cancers such as breast cancer, gastric cancer, pancreatic cancer, and liver
cancer. Therefore, the regulatory mechanism of Twist1 needs to be researched to identify proper therapeutic strategies. To identify and confirm the anti-cancer effect of a chemical, 3-acetyl-5,8-dichloro-2-((2,4-dichlorophenyl)amino)quinolin-4(1H)-one (ADQ), on a liver cancer cell line, various cell-based assays were performed in this study. The scaffold structure of ADQ was previously reported to have activity toward several proteases. In this study, the effects of ADQ suppressing cancer cell migration and invasion were evaluated comprehensively using various liver cancer-derived cell lines, including several HCC such as Huh7, Hep3B, and PLC-PRF-5 and a liver endothelial cancer cell line, SK-Hep1.

Results

**ADQ suppressed the cancerous physiologies of liver cancer cells**

The chemical compound library (~3,300 compounds) was screened through wound healing assays with SK-Hep1 cells. The compound ADQ (Fig. 1A) was identified as one of the most potent inhibitors among the 3,300 compounds screened (Fig. S1A). SK-Hep1 cells treated with 10 μM ADQ showed a significant reduction in cell viability (Fig. S1B). Therefore, ADQ was applied at a maximum concentration of 5 μM in the following assays. The ability of ADQ to suppress the migration of cancer cells was examined using wound healing assays (Fig. 1B). The migratory ability of the cells was significantly decreased by ADQ treatment. The wound closure of the cells treated with the ADQ was only around 50% of the control, which represents significant suppression of cell migration. In addition, the inhibitory effect of ADQ on wound closure was similar to that of emodin (20 μM), a well-known tumor suppressor compound for various cancer types. The invasion assays were performed using Matrigel to investigate the effect of ADQ (Fig. 1C). SK-Hep1 cells treated with increasing concentrations of ADQ showed less invasion than the ADQ-untreated control. ADQ showed dramatic suppression of cell invasion at a relatively lower concentration than emodin. The invasion of other liver cancer cells, Huh7 and PLC-PRF-5, was also notably inhibited by ADQ (Fig. S1C). Gelatin zymography was performed to evaluate the effect of ADQ on the activities of MMPs (Fig. 1D). The protease activities of MMP-2 and -9 were inhibited by treatment with ADQ. In particular, the MMP-2 activity was almost entirely suppressed by ADQ. The inhibition of MMP activities was also confirmed by MMP enzymatic activity assay (Fig. 1E). Cancer cells that are going through metastatic progression also show anchorage-independent growth. Therefore, a soft-agar colony formation assay was performed to observe the effect of ADQ on the anchorage-independent growth of SK-Hep1 cells (Fig. 1F). During colony formation in the 0.3% soft agar, ADQ showed notable inhibition of colony formation. These data indicate that ADQ inhibits the cancerous physiologies of SK-Hep1 cells, including cell migration, invasion, anchorage-independent growth, and MMP activities.

**Invasion of multicellular tumor spheroid (MTS) was inhibited by ADQ**

MTS growth or invasion assays have been utilized to study cancer cell growth and screen anti-cancer drugs because this three-dimensional (3D) culture system mimics the microenvironment of cancer cells that grow in multi-layers and invade into adjacent tissues. In our study, an MTS invasion assay was performed to identify the effect of ADQ in conditions similar to the *in vivo* cancer microenvironment. In
comparison to ADQ-untreated MTS, which invaded into the surrounding Matrigel, MTS treated with ADQ showed lesser invasion (Fig. 2). Comparing the yellow outline of MTS observed at the 0 h-time point to the spheroids at each subsequent time point, the MTS invasions were dose-dependently suppressed by ADQ treatment. When the MTS was incubated with 5 μM ADQ, the invasion of MTS was almost completely repressed, which was a more substantial effect than 40 μM emodin treatment. These results suggest that ADQ has the potential to inhibit the invasion of cancer cells in vivo.

**ADQ showed anti-cancer effects via the Akt pathway**

The various intracellular signaling pathways were analyzed to sort out the target pathway of ADQ, and ADQ suppressed the Akt pathway (Fig. 3A). The SK-Hep1 cells were treated with LY294002, a PI3K inhibitor, to inhibit the Akt activation specifically. The cells treated with LY294002 showed suppression in wound healing, migration, and invasion as similar to the cells treated with ADQ (Fig. S2). In addition, The Akt pathway has been reported to regulate cell survival. The apoptosis-related proteins were evaluated to investigate whether the suppressed cell growth was due to apoptosis. The levels of the pro-apoptotic protein BAX were not significantly affected by ADQ treatment (Fig. 3B). The levels of p53 that induce apoptosis were also not altered by ADQ, indicating that the anti-cancer effects of ADQ are not significantly correlated with apoptosis.

The FoxO transcription factor is regulated by Akt, and it induces the expression of CDKIs. The promoter activity of the manganese superoxide dismutase (MnSOD) gene (sod2), a FoxO target gene, was evaluated by luciferase reporter assays. The SOD promoter activity was significantly up-regulated by 5 μM ADQ, which suggests that FoxO activity is increased in response to ADQ (Fig. 3C). In addition, the mRNA levels of the CDKI genes that are FoxO target genes were evaluated by RT-PCR after treatment with ADQ. The transcriptional levels of CDKN1A, CDKN1B, CDKN2B, and CDKN2D were increased by ADQ (Fig. 3D). The levels of the p21 protein, which is encoded by the CDKN1A gene, were also increased by ADQ (Fig. 3E). The cell cycle distribution was evaluated during treatment with ADQ. Cells treated with ADQ showed an increased population in the G0/G1 phase and a decreased population in the G2/M phase (Fig. 3F). When cells were treated with 5 μM ADQ, cell populations in both G0/G1 and the G2/M phase showed significant changes. Cell proliferation was observed to evaluate the anti-cancer effect of ADQ further. Treatment with ADQ successfully suppressed the growth of SK-Hep1 cells (Fig. 3G). Cell growth was almost completely repressed by 5 μM ADQ. Furthermore, the effect of ADQ on cellular growth was also evaluated in 3D culture using MTS (Fig. S3). The MTS growth was measured without Matrigel to observe only the growth. When ADQ was added, the growth of the MTS was suppressed compared to the control. Taken together, these data suggest that the Akt pathway is inhibited by ADQ, which results in cell cycle arrest, not apoptotic cell death.

**The Twist1 transcription factor was down-regulated by ADQ**

To further investigate the regulatory mechanisms of ADQ, luciferase reporter assays were performed (Fig. S4). Various promoter activities were measured via the reporter system, including the urinary-type
plasminogen activator (uPA), uPA receptor (uPAR), heparanase-1, and E-cadherin promoters. Notably, the E-cadherin promoter activity was increased (Fig. S4D). As the alteration in E-cadherin expression is a hallmark of cancer development, ADQ was further analyzed for its molecular regulatory mechanisms. ADQ was applied for the indicated time, and Twist1 levels were observed along with the level of Akt phosphorylation by immunoblot analysis (Fig. 4A). Twist1 and phospho-Akt levels were decreased by ADQ treatment. The decrease in p-Akt and Twist1 levels was also observed in other liver cancer cell lines, such as Hep3B and Huh7 cells (Fig. S5). In addition, a reduction of the Twist1 expression level was observed earlier than the inhibition of Akt phosphorylation (Fig. S6), which suggests the possibility that Twist1 regulates the phosphorylation of Akt. The overexpression or knockdown of Twist1 showed no dramatic effects on either Akt expression or its phosphorylation level (Fig. 4B and S7A). Furthermore, when Akt wild-type or inactive mutant was overexpressed, the endogenous expression levels of Twist1 were not altered (Fig. 4C). These data indicate that the effects of ADQ on Akt phosphorylation and Twist1 expression should be independent.

The suppressive effects of ADQ on Twist1 expression were investigated at the transcriptional and translational levels. The transcriptional levels of TWIST1 were not altered by ADQ treatment (Fig. 4D). When the SK-Hep1 cells were treated with ADQ, the Twist1 protein expression level was down-regulated as observed previously, but its down-regulation was abolished by treatment with MG132, a potent inhibitor of the proteasome (Fig. 4E). Altogether, these data indicate that the decreased Twist1 by ADQ is mediated by the regulation of Twist1 protein degradation rather than its gene expression. When the Twist1 protein level was reduced in the cells treated with ADQ dose-dependently, E-cadherin expression was induced, and N-cadherin expression was suppressed (Fig. 4F). It was also observed that when the endogenous Twist1 level was decreased with siRNA transfection, cell migration and invasion were inhibited as shown with ADQ treatment (Fig. S7). These data demonstrate that ADQ treatment leads to the inhibition of the Twist1 expression, which results in the alteration of cadherin expressions and the suppression of further progression of cancer (Fig. 4G).

Discussion

Most cancer mortality can be attributed to metastasis that occurs during cancer progression 20. Thus, targeting developing cancer provides a novel therapeutic approach. In this study, we identified a potent cancer inhibitor, ADQ, and evaluated its anti-cancer mechanisms at cellular and molecular levels.

The anti-proliferative effects of ADQ were shown in our study to be mediated by suppression of the Akt pathway. Activation of the Akt pathway generally leads to increased proliferation and suppressed apoptosis or autophagy 21. The FoxO transcription factor is phosphorylated by Akt and then exported from the nucleus 6. The suppression of Akt phosphorylation by ADQ led to up-regulated FoxO activity, which was observed in luciferase reporter assays and by the expression levels of CDKIs. Increased expression of p21 encoded by the CDKN1A gene was observed at both the transcriptional and translational levels. It is a crucial CDKI in FoxO-induced G1 cell cycle arrest 7. Therefore, the alteration of the cell cycle distribution and subsequent suppression of cell proliferation by ADQ was possibly mediated
via the Akt pathway regulation. Although ADQ did not show significant cytotoxicity up to ~5 μM, the cell proliferation was inhibited, which showed notably different pattern that might be affected by the starting cell density of each assay. Interestingly, this cell cycle arrest induced by Akt inhibition/FoxO activation often leads cells to a quiescent state rather than to cell deaths. As FoxO has a potential role in suppressing liver fibrosis via cell cycle arrest, ADQ may have effects on preventing hepatic fibrosis.

ADQ rapidly reduced the Twist1 protein level, which raised the possibility that the regulation of Twist1 by ADQ is not dependent on the Akt pathway. The expression of Twist1 did not alter Akt expression and vice versa, suggesting that ADQ regulates the Akt activation and Twist1 stability independently on each other. The protein level of Twist1 was significantly reduced by ADQ treatment in various liver cancer cell lines, including SK-Hep1, Huh7, and Hep3B. Since Twist1 is associated with drug resistance in various cancer types, the application of ADQ may have benefit as a novel therapeutic, targeting liver cancer by inhibiting Twist1. Interestingly, a previous study reported an inhibitor that suppressed Twist1 expression level at working concentrations over 10 μM in oncogene-driven lung cancer. Since ADQ showed a sufficient reduction of Twist1 at 5 μM in our study, this suggests that ADQ is efficient in suppressing Twist1 levels and can be developed as a drug candidate for treating multiple cancer types.

ADQ showed potential anti-cancer effects through regulation of the Akt pathway and Twist1 protein level in our study. To further evaluate ADQ in the molecular regulation of the metastasis-associated pathways, the regulatory mechanisms of the Akt pathway and Twist1 by ADQ needs to be verified in different cancer types, which is our next research goal.

**Methods**

**Chemical screening**

A chemical compound library (~3,300 compounds) contains 1) compounds extracted from natural products and 2) re-positioning chemical drugs. This library was provided by the Korea Chemical Bank (www.chembank.org). The library was screened through wound healing assays of the human liver cancer cell line, SK-Hep1. SK-Hep1 cells (2 × 10⁴ cells/well) were seeded in 96-well plates and incubated overnight. The wound was made by scratching with a pipette tip, and the detached floating cells were removed. Each compound was applied to the cells at 1 μM concentration in 1% FBS media, and the cells were incubated at 37 °C for 24 h. The wound area at 0 h and 24 h was observed with a JuLI Stage Real-Time Cell History Recorder. Wound closure was calculated as \((X_0 - X_{24}) / X_0 * 100 (%)\), where \(X_N\) indicates the wound area at N-h point. The values were plotted as a heatmap using “ComplexHeatmap” package in R (version 4.0.1). A literature search was followed using the chemical structures of initially screened compounds provided by the Korea Chemical Bank upon request. ADQ was selected for further evaluation because there were no previous reports of the anti-cancer effects of ADQ.

**Cell culture**
The SK-Hep1, Huh7, Hep3B, and PLC-PRF-5 cell lines were purchased from the Korean Cell Line Bank (Seoul, Korea). SK-Hep1 and Hep3B cells were grown in Dulbecco's modified Eagle's medium (DMEM). Huh7 cells were grown in Roswell Park Memorial Institute (RPMI) 1640 medium, and PLC-PRF-5 cells were grown in RPMI 1640 containing 25 mM HEPES. All cell culture media contains 10% fetal bovine serum (FBS), 50 μg/ml streptomycin, and 50 U/ml penicillin (GIBCO BRL, Grand Island, NY, USA). Cells were grown at 37°C, 5% CO₂.

**Reagents**

Rabbit polyclonal anti-Akt (cat. No. sc-8312), rabbit polyclonal anti-p-Akt (Ser473, cat. No. sc-7985), mouse monoclonal anti-Twist1 (cat. No. sc-81417), mouse monoclonal anti-p53 (cat. No. sc-126), rabbit polyclonal anti-p21 (cat. No. sc-397), rabbit polyclonal anti-BAX (cat. No. sc-493), and mouse monoclonal anti-α-tubulin (cat. No. sc-5286) were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA). Mouse monoclonal anti-E-cadherin (cat. No. 610182) and mouse monoclonal anti-N-cadherin (cat. No. 610720) antibodies were purchased from BD Biosciences (San Jose, CA, USA). All primary antibodies were diluted at the ratio of 1:1000 in 3% bovine serum albumin. Polyclonal anti-mouse IgG Fc-HRP (cat. No. LF-SA8001) and polyclonal anti-rabbit IgG-HRP (cat. No. LF-SA8002) were purchased from AbFrontier (Young In Frontier Co., Ltd., Seoul, Korea) and diluted at 1:5000. LY294002 (cat. No. #440202-5MGCN, 5mg) was purchased from Calbiochem (San Diego, CA, USA).

**Cell viability assay**

Cells were seeded in 96-well plates (4 × 10⁴ cells/well) and treated with ADQ for 24 or 48 h with 10% FBS media. Cell viability was evaluated using the EZ-Cytox solution (Daeil Lab, Seoul, Korea) according to the manufacturer's instructions. The optical densities (OD) of the supernatants were measured at 450 nm using a Synergy H1 Microplate Reader (BioTek Instruments, Winooski, VT, USA).

**Wound healing assay**

The cells were seeded in 6-well plates (1.2 × 10⁶ cells/well). The wound was made with a scratcher tip (0.5 mm; SPL Life Sciences, Gyeonggi-do, Korea) 24 h after cell seeding. Then the cells were treated with ADQ in 1% FBS media for 24 h. The wound area was observed with a JuLI Stage Real-Time Cell History Recorder (NanoEnTek Inc., Seoul, Korea). The wound closure is represented as the percent of wound recovery. All experiments were performed in triplicate.

**Migration and invasion assay**

For invasion assay, transwells (24-well type, pore size 8 μm) were coated with Matrigel (0.5 mg/ml; BD Biosciences, Franklin Lakes, NJ, USA) for 2 h. The cells (2 × 10⁵ cells/well) in 1% FBS media were added to the upper chamber along with ADQ, and the lower chamber was filled with 10% FBS media. After incubation at 37 °C for 6 h (for migration assay) or 21 h (for invasion assay), the membranes were fixed for 10 min in 3.7% paraformaldehyde. The migrated or invaded cells were stained with 0.5% crystal violet.
for 10 min. The cells on the upper surface of the membrane were removed with a cotton swab. After being dried, five random fields of the membrane were observed at ×100 magnification.

**Gelatin zymography**

Cells were seeded in 12-well plates (2 × 10^5 cells/well) for 16 h. ADQ was added to the cells in serum-free media for 24 h. The collected media were mixed with 5× sample buffer without β-mercaptoethanol. The samples were analyzed by gelatin zymography using 0.1% gelatin-containing 10% acrylamide SDS-PAGE. After gel electrophoresis, the gel was washed with the wash buffer [2.5% Triton X-100, 50 mM Tris-HCl (pH 7.5), 5 mM CaCl₂, 1 μM ZnCl₂, 0.016% NaN₃] for 30 min at room temperature (RT). Then, the gel was incubated in the substrate buffer [1% Triton X-100, 50 mM Tris-HCl (pH 7.5), 5 mM CaCl₂, 1 μM ZnCl₂, 0.016% NaN₃] for 24 h at 37 °C. For the visualization, the gel was stained with Coomassie Blue for 30 min at RT and then destained with a methanol/acetic acid solution for 1 h at RT.

**MMP activity assay**

SK-Hep1 cells were seeded in 12-well culture plates. The cultured medium changed to serum free medium containing ADQ with indicated concentration. The medium was collected after 24 h. The collected medium was incubated with an assay system according to the manufacturer's instructions of EnzChek™ Gelatinase/Collagenase Assay Kit (E12055, Thermo Fisher Scientific, Inc., USA). The fluorescence was measured with (microplate reader).

**Soft-agar colony formation assay**

SK-Hep1 cells (4500 cells/well) were mixed with 0.3% agarose (Sigma–Aldrich, St. Louis, MO, USA), and the mixture was seeded on 0.5% agarose in 12-well plates. The media with ADQ was replaced every 3 d. After incubation for 14 d, the colonies were stained with a 0.05% crystal violet solution. The stained samples were photographed by a digital camera (Olympus SP-350; Cam2Com).

**MTS invasion assay**

SK-Hep1 cells were seeded in low-attachment 96-well plates (2000 cells/well) and incubated for 3 days. After media removal, Matrigel (3 mg/ml; BD Biosciences, Franklin Lakes, NJ, USA) was added. The plate was centrifuged at 300 g for 3 min at 4°C and then incubated at 37°C and 5% CO₂ overnight. The spheroids were treated with ADQ in 10% FBS media. All images were captured by a JuLI Stage Real-Time Cell History Recorder (NanoEnTek Inc., Seoul, Korea).

**Immunoblot analysis**

After the cells were treated with ADQ for 24 h or transfected with the indicated plasmid for 48 h, cell lysates were harvested with lysis buffer [20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 0.5% Triton X-100, 0.5% IGEPAL® CA-630, 1 mM EDTA, 1% glycerol, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and 1 mM Na₃VO₄]. The protein concentrations were determined by a Bradford protein assay (Bio-Rad Laboratories,
Inc.) according to the manufacturer's protocol. Equal amounts of protein samples were boiled in 5× SDS sample buffer [12 mM Tris-HCl (pH 6.8), 5% glycerol, 0.4% SDS, 1% β-mercaptoethanol, and 0.02% bromophenol blue] at 100°C for 5 min. Samples were separated by 12% SDS-PAGE and transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat-dried skimmed milk for 1 h at 25°C and then they were incubated for 16 h at 4°C with a specific primary antibody diluted in 3.3% BSA in 1× TBST [Tris-buffered saline with 0.05% Tween 20]. The membranes were washed several times with 1× TBST and then incubated with the appropriate secondary antibody for 2 h at 25°C. Protein bands were detected by enhanced chemiluminescence immunoblotting detection reagent (Pierce; Thermo Fisher Scientific, Inc.). All immunoblot analysis was performed at least three times. The band intensities of each protein were analyzed with ImageJ (https://imagej.nih.gov/ij/).

**Reverse transcription-polymerase chain reactions (RT-PCR) analysis**

SK-Hep1 cells were seeded in 12-well plates (2 × 10⁵ cells/well). Cells were treated with ADQ (0, 2, and 5 µM) for 24 h. Total RNA was prepared using the Accuzol total RNA extraction solution (Bioneer Corporation, Daejeon, Korea). Total RNA (1 µg) was reverse transcribed into complementary DNA (cDNA) using a TOPscript cDNA synthesis kit (ENzynomics, Daejeon, Korea). Briefly, the amplification conditions were as follows: 95°C (5 min) initial denaturation followed by 25 cycles of 95°C for 5 sec and annealing/extension at 55°C (30 sec). The gene expression levels were normalized relative to the reference gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Primer sequences used are described here. *GAPDH* sense, 5'-gtcttcaccacccatggagaagg-3'; antisense, 5'-ccgtcctccacacctttcttgat-3'; *CDKN1A* sense, 5'- cagtggacacgcagccagctgag-3'; antisense, 5'-ggaccccttagcctggctccc-3'; *CDKN1B* sense, 5'-taattgggctccggctaact-3'; antisense, 5'-ccctccctcttcacaaagttta-3'; *CDKN2B* sense, 5'-ctgtggaagaagggagagctgctgcctgggtgagat-3'; antisense, 5'-aacggttgacgtcggcgtggagat-3'; *CDKN2D* sense, 5'-cctgtgcatcatctgccagctggagat-3'; antisense, 5'-ggcctgagaaaaagagagagat-3'; *TWIST1* sense, 5'-acgtgatcaggtcgctggctggctgcttc-3'; antisense, 5'-tgagtcaggtcgctggctggcttc-3'.

**Cell cycle analysis**

SK-Hep1 cells (1 × 10⁶ cells) were treated with ADQ for 24 h in 10% FBS media. Harvested cells were fixed in 70% cold ethanol at -20 °C for 3 h. The fixed cells were washed with PBS and stained with 50 µg/ml of propidium iodide (Sigma–Aldrich, St. Louis, MO, USA) for 30 min at 25°C in the dark. The DNA content of each sample was analyzed by a Guava® Muse® Cell Analyzer (Luminex Corporation, Austin, TX, USA).

**Cell growth assay**

SK-Hep1 cells (1500 cells/well) were seeded into 96-well plates. ADQ (0, 2, and 5 µM) was added in 10% FBS media for 96 h. Cell growth was evaluated using the EZ-Cytox solution according to the manufacturer's instructions.

**MTS growth assay**
SK-Hep1 cells (2000 cells/well) were seeded on 1% agarose-coated 96-well plates. The cells were incubated for 16 h, and then the formed spheroids were treated with ADQ in 10% FBS media for 96 h. Images were captured with 24-h interval by a JuLI Stage Real-Time Cell History Recorder.

**Luciferase reporter assay**

SK-Hep1 cells (5 × 10⁶ cells/well) were seeded in 100-mm dishes and co-transfected with a pE-cadherin-Luc cis-reporter plasmid (Agilent Technology Inc., Santa Clara, CA, USA) and a gWIZ-GFP plasmid. The other luciferase reporter plasmids containing the uPAR (-682/+27) (pcDNA3.1-uPAR (-682/+27)-Luc), uPA (-810/+30) (pcDNA3.1-uPA (-810/+30)-Luc), or HPR1 (-462/+98) promoter region (pcDNA3.1-HPR1(-462/+98)-Luc) were constructed with the insertion of PCR products into the BgIII and EcoRI sites of the plasmid pcDNA3.1-Luc. The pNF-κB-Luc or pAP1-Luc reporter plasmids (Agilent Technologies Inc.) contained the NF-κB or AP1 promoter, respectively. In addition, the pSOD-luc plasmid was a kind gift from Prof. Jongkyeong Chung (Seoul National University, Seoul, Korea). Transfected cells were divided into 12-well plates (1 × 10⁵ cells/well) and incubated for 24 h. Then the cells were treated with the indicated concentrations of the compound for an additional 24 h. The cells were lysed with Cell culture lysis reagent (Promega Corporation, Fitchburg, WI, USA), and luciferase activities were measured according to the instructions of the manufacturer (Promega, Madison, WI, USA). The luciferase activities were normalized against the level of GFP expression.

**Twist1 siRNA transfection**

Twist1 siRNA and scrambled negative control were purchased from Bioneer (Daejeon, Korea). Twist1 siRNA #1 sense, 5’-CUG AAC AGU UGU UUG UGU U-3’; antisense, 5’-AAC ACA AAC AAC UGU UCA G-3’; #2 sense, 5’-GGA CCC AUG GUA AAA UGC A; antisense, 5’-UGC AUU UUA CCA UGG GUC C; #3 sense, 5’-GCG CUU UCU UGU UGG ACC U; antisense, 5’-AGG UCC AAA AAG AAA GCG C; scrambled negative control sense, 5’-CCU ACG CCA CCA AUU UCG U-3’; antisense, 5’-ACG AAA UUG GUG GCG UAG G-3’. A mixture of 100 nM siRNA and 5 μl Lipofectamine 2000 (Thermo Fisher Scientific Inc, MA, USA) was incubated in serum-free media for 30 min at RT. After incubation, the mixture was added to SK-Hep1 cells for siRNA transfection.

**Statistical analysis**

All data are expressed as means ± standard error of the mean (SEM). Statistical analysis of the data was performed by one-way ANOVA using Prism 3.0 (GraphPad Software, San Diego, CA, USA). \( P<0.05, p<0.01, \) and \( p<0.001 \) were considered to be statistically significant.

**Declarations**

**Acknowledgments**
This research was supported by a National Research Foundation of Korea (NRF) grant, funded by the Ministry of Science and ICT (NRF2018R1A2B6005084, 2018M3A9B5060244, and 2015R1A5A1008958). The authors thank the Korea Chemical Bank (www.chembank.org) for kindly providing the chemical library for the screening and Prof. Jongkyeong Chung (Seoul National University, Seoul, Korea) for providing the pSOD-luc plasmid.

Author Contributions

S.C. and S.E.R. conceptualized this study and acquired the funding. S.C. supervised and administrated the project. H.K.L. provided and edited the methodology. J.H., S.L., J.P., J.S., E.K., H.Y., and B.R.K. performed and validated the assays. J.H., S.L., J.P., J.S., E.K., and H.Y. analyzed and visualized the data. H.K.L. provided the resources. S.C. and J.H. curated the data. J.H. wrote and prepared an original draft. S.C., S.E.R., and J.H. reviewed and edited the manuscript. All authors have read and agreed to the published version of the manuscript.

Competing interests

The authors declare no conflict of interest.

Data availability

All data generated or analysed during this study are included in this published article (and its Supplementary Information files).

References

1 Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68, 394-424, doi:10.3322/caac.21492 (2018).

2 Yilmaz, M. & Christofori, G. EMT, the cytoskeleton, and cancer cell invasion. *Cancer Metastasis Rev* 28, 15-33, doi:10.1007/s10555-008-9169-0 (2009).

3 Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y. & Johnson, K. R. Cadherin switching. *J Cell Sci* 121, 727-735, doi:10.1242/jcs.000455 (2008).

4 Xu, N., Lao, Y., Zhang, Y. & Gillespie, D. A. Akt: a double-edged sword in cell proliferation and genome stability. *J Oncol* 2012, 951724, doi:10.1155/2012/951724 (2012).

5 Paplomata, E. & O'Regan, R. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. *Ther Adv Med Oncol* 6, 154-166, doi:10.1177/1758834014530023 (2014).

6 Tzivion, G., Dobson, M. & Ramakrishnan, G. FoxO transcription factors; Regulation by AKT and 14-3-3 proteins. *Biochim Biophys Acta* 1813, 1938-1945, doi:10.1016/j.bbamcr.2011.06.002 (2011).
7 Zhang, X., Tang, N., Hadden, T. J. & Rishi, A. K. Akt, FoxO and regulation of apoptosis. *Biochim Biophys Acta* **1813**, 1978-1986, doi:10.1016/j.bbamcr.2011.03.010 (2011).

8 Kunter, I. *et al.* Active form of AKT controls cell proliferation and response to apoptosis in hepatocellular carcinoma. *Oncol Rep* **31**, 573-580, doi:10.3892/or.2013.2932 (2014).

9 De Craene, B. & Berx, G. Regulatory networks defining EMT during cancer initiation and progression. *Nat Rev Cancer* **13**, 97-110, doi:10.1038/nrc3447 (2013).

10 Chaffer, C. L., San Juan, B. P., Lim, E. & Weinberg, R. A. EMT, cell plasticity and metastasis. *Cancer Metastasis Rev* **35**, 645-654, doi:10.1007/s10555-016-9648-7 (2016).

11 Qin, Q., Xu, Y., He, T., Qin, C. L. & Xu, J. M. Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms. *Cell Res* **22**, 90-106, doi:10.1038/cr.2011.144 (2012).

12 Yang, J. *et al.* Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. *Cell* **117**, 927-939, doi:10.1016/j.cell.2004.06.006 (2004).

13 Kang, D. H. *et al.* Identification of 3-Acetyl-2-aminoquinolin-4-one as a Novel, Nonpeptidic Scaffold for Specific Calpain Inhibitory Activity. *J Med Chem* **52**, 3093-3097, doi:10.1021/jm8014734 (2009).

14 Wei, W. T., Lin, S. Z., Liu, D. L. & Wang, Z. H. The distinct mechanisms of the antitumor activity of emodin in different types of cancer (Review). *Oncol Rep* **30**, 2555-2562, doi:10.3892/or.2013.2741 (2013).

15 Mori, S. *et al.* Anchorage-independent cell growth signature identifies tumors with metastatic potential. *Oncogene* **28**, 2796-2805, doi:10.1038/onc.2009.139 (2009).

16 Zhang, X. *et al.* Development of an in vitro multicellular tumor spheroid model using microencapsulation and its application in anticancer drug screening and testing. *Biotechnol Prog* **21**, 1289-1296, doi:10.1021/bp050003l (2005).

17 Ho, W. Y., Yeap, S. K., Ho, C. L., Rahim, R. A. & Alitheen, N. B. Development of multicellular tumor spheroid (MCTS) culture from breast cancer cell and a high throughput screening method using the MTT assay. *Plos One* **7**, e44640, doi:10.1371/journal.pone.0044640 (2012).

18 Sant, S. & Johnston, P. A. The production of 3D tumor spheroids for cancer drug discovery. *Drug Discov Today Technol* **23**, 27-36, doi:10.1016/j.ddtec.2017.03.002 (2017).

19 Chi, S. W. Structural insights into the transcription-independent apoptotic pathway of p53. *BMB Rep* **47**, 167-172, doi:10.5483/bmbrep.2014.47.3.261 (2014).

20 Steeg, P. S. Targeting metastasis. *Nat Rev Cancer* **16**, 201-218, doi:10.1038/nrc.2016.25 (2016).

21 Gozuacik, D. & Kimchi, A. Autophagy as a cell death and tumor suppressor mechanism. *Oncogene* **23**, 2891-2906, doi:10.1038/sj.onc.1207521 (2004).
22 Leontieva, O. V., Demidenko, Z. N. & Blagosklonny, M. V. Contact inhibition and high cell density deactivate the mammalian target of rapamycin pathway, thus suppressing the senescence program. *Proc Natl Acad Sci U S A* **111**, 8832-8837, doi:10.1073/pnas.1405723111 (2014).

23 Kops, G. J. *et al.* Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. *Mol Cell Biol* **22**, 2025-2036, doi:10.1128/mcb.22.7.2025-2036.2002 (2002).

24 Kops, G. J. *et al.* Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. *Nature* **419**, 316-321, doi:10.1038/nature01036 (2002).

25 Adachi, M. *et al.* The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells. *Gastroenterology* **132**, 1434-1446, doi:10.1053/j.gastro.2007.01.033 (2007).

26 Roberts, C. M. *et al.* TWIST1 drives cisplatin resistance and cell survival in an ovarian cancer model, via upregulation of GAS6, L1CAM, and Akt signalling. *Sci Rep* **6**, 37652, doi:10.1038/srep37652 (2016).

27 Zhang, X. *et al.* Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells. *Int J Cancer* **120**, 1891-1898, doi:10.1002/ijc.22489 (2007).

28 Wang, X. *et al.* Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. *Oncogene* **23**, 474-482, doi:10.1038/sj.onc.1207128 (2004).

29 Cheng, G. Z. *et al.* Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. *Cancer Res* **67**, 1979-1987, doi:10.1158/0008-5472.CAN-06-1479 (2007).

30 Yochum, Z. A. *et al.* A First-in-Class TWIST1 Inhibitor with Activity in Oncogene-Driven Lung Cancer. *Mol Cancer Res* **15**, 1764-1776, doi:10.1158/1541-7786.MCR-17-0298 (2017).